Johnson & Johnson ($JNJ) and AbbVie ($ABBV) have snagged the indication for standout cancer med Imbruvica that they've been waiting for. On Friday, the FDA granted ...
AbbVie and Johnson & Johnson’s Imbruvica is under increasing pressure from new in-class competitors, but the pair hopes a new combination and longer-term data could help consolidate its lead in ...